Saturday 17 October 2026
Export TRVN’s income statement to Excel — free account
Trevena, Inc.
TRVN Healthcare Biotechnology
Revenue growth for three consecutive years, operating cash flow growth for three.
0.00
0.07
−100.00%
Follow TRVN
| Sep '24 | Jun '24 | Mar '24 | Dec '23 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
1 | — | — | — |
+8 more TTM periods Free account |
| 344.49% | 807.12% | 1,784.36% | (1,014.58%) | ||
| (105.83%) | (119.82%) | (115.65%) | (90.25%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(355.58%) | (267.48%) | (201.97%) | (139.67%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(31.76) | (36.96) | (37.06) | (64.93) | |
Free Cash Flow |
(27.09) | (31.51) | (31.58) | (33.08) | |
Capital Expenditures |
— | — | — | (0.04) | |
| Other line items | |||||
Cash ROIC |
(116.23%) | (108.91%) | (71.18%) | (58.93%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
1.29 | 0.90 | 0.82 | 0.71 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
211.40 | 251.02 | 520.76 | 503.35 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
2,404.95% | 3,504.51% | 522.11% | 522.66% | |
Selling, General and Administrative Expense of Revenue |
3,284.62% | 4,204.51% | 642.43% | 653.12% | |
Share Based Compensation of Revenue |
468.50% | 607.45% | 89.36% | 93.76% | |
Interest Coverage |
(11.07) | (11.37) | (9.44) | (9.68) | |
Operating CF/Net income |
0.80 | 0.85 | 0.79 | 0.82 | |
Depreciation/Fixed assets |
0.39 | 0.34 | 0.31 | 0.28 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | (0.12) | |
Revenue per Share |
0.64 | 0.52 | 3.68 | 6.13 | |
Operating CF per Share |
(31.76) | (36.96) | (37.06) | (64.85) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.08) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.01 |
Columns are period end dates